Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients

Go back to Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Regeneron (NASDAQ: REGN) Delayed: 927.89 +109.12 (13.33%)
Previous Close $818.77    52 Week High $592.36 
Open $869.43    52 Week Low $325.35 
Day High $935.35    P/E 243.54 
Day Low $839.08    EPS $3.81 
Volume 2,870,901       

BANCO SANTANDER S.A. (NYSE: SAN) Delayed: 11.19 -0.42 (3.62%)
Previous Close $11.61    52 Week High $5.58 
Open $11.38    52 Week Low $3.60 
Day High $11.39    P/E N/A 
Day Low $11.12    EPS $0.00 
Volume 10,251,707       

SANOFI (NASDAQ: SNY) Delayed: 44.34 +1.21 (2.81%)
Previous Close $43.13    52 Week High $44.76 
Open $44.82    52 Week Low $36.81 
Day High $45.30    P/E N/A 
Day Low $44.23    EPS $0.00 
Volume 15,302,156